The New Year has arrived with a bang, as Teva put out a press release on Jan 1st revealing that its CEO, Shlomo Yanai, is stepping down in May, to be replaced by Dr Jeremy Levin, a former executive with Bristol-Myers Squibb. Given that...
The revolving door continues to spin: Siggi Olafsson moves to Watson
Having left Actavis in order to make way for Claudio Albrecht (see news item of June 23rd 2010), Siggi Olafsson has now reappeared at Watson, where he will take over the role of Executive VP, Global Generics and will be resposible for driving Watson’s...
Claudio Albrecht arrives at Actavis and signals a change of tack by Deutsche Bank
Actavis announced today that Claudio Albrecht has been appointed its new CEO, replacing Siggi Oli Olafsson, who had held the position for the last three years, following the departure of Robert Wessman. As far as we are aware, this was a shareholder-driven move, with...